ENDRA Life Sciences Files 8-K
Ticker: NDRA · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1681682
| Field | Detail |
|---|---|
| Company | Endra Life Sciences INC. (NDRA) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, corporate-events
TL;DR
ENDRA Life Sciences dropped an 8-K on 8/28 - check for Reg FD, other events, and financials.
AI Summary
ENDRA Life Sciences Inc. filed an 8-K on August 28, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is based in Ann Arbor, MI.
Why It Matters
This 8-K filing provides updates on ENDRA Life Sciences' corporate activities, including regulatory disclosures and financial information, which are important for investors to monitor.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard corporate events and disclosures, not indicating immediate significant risk.
Key Players & Entities
- ENDRA Life Sciences Inc. (company) — Registrant
- August 28, 2024 (date) — Date of Report
- Ann Arbor, MI (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific events are disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure but does not detail the specific events within the provided text.
What type of financial statements are included in the filing?
The filing mentions 'Financial Statements and Exhibits' but does not specify the nature or period of these statements.
When was ENDRA Life Sciences Inc. previously known as Endra Inc.?
The company's name changed from Endra Inc. to ENDRA Life Sciences Inc. on August 5, 2016.
What is ENDRA Life Sciences Inc.'s Standard Industrial Classification code?
The SIC code for ENDRA Life Sciences Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
What is the principal executive office address for ENDRA Life Sciences Inc.?
The principal executive offices are located at 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-28 17:09:43
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
Filing Documents
- endra_8k.htm (8-K) — 23KB
- endra_ex991.htm (EX-99.1) — 10KB
- 0001654954-24-011213.txt ( ) — 158KB
- endra-20240828.xsd (EX-101.SCH) — 6KB
- endra-20240828_lab.xml (EX-101.LAB) — 14KB
- endra-20240828_cal.xml (EX-101.CAL) — 1KB
- endra-20240828_pre.xml (EX-101.PRE) — 9KB
- endra-20240828_def.xml (EX-101.DEF) — 2KB
- endra_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 28, 2024, ENDRA Life Sciences Inc. issued a press release (the "Press Release") disclosing the fact that it has been provided an extension from a Hearing Panel of the Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. A copy of the press release is furnished herewith as Exhibit 99.1. The information furnished under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events As disclosed in the Press Release, as of August 28, 2024, the Company has 17,280,655 shares of common stock outstanding.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 28, 2024, furnished herewith. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. August 28, 2024 By: /s/ Richard Jacroux Name: Richard Jacroux Title: Chief Financial Officer 3